Physician profile
Ida E Sutherland
NPI 1003925108
$6,410.05
in general payments reported to CMS, 2019-2025
38 companies · $1,697 in 2025
The $1,697 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $793 · 2022: $845 · 2023: $1,358 · 2024: $1,717 · 2025: $1,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,772.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $915.29 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $796.43 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $619.32 | 2021-2025 | |
| Pfizer INC. | $503.23 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $374.48 | 2021-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $344.27 | 2022-2025 | Rexulti |
| Abbott Laboratories | $303.07 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $240.35 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.30 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $199.94 | 2021-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $195.83 | 2021-2025 | |
| Amgen INC. | $184.64 | 2021-2025 | Otezla, Repatha, Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $167.88 | 2025 | Caplyta |
| Astellas Pharma US INC | $146.60 | 2022-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $107.13 | 2024-2025 | Voquezna |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $105.78 | 2021-2024 | Nexletol |
| Vanda Pharmaceuticals INC. | $102.79 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $82.88 | 2024-2025 | Sunosi, Auvelity |
| Lilly USA, LLC | $81.47 | 2023-2024 | Jardiance |
| Lundbeck LLC | $77.89 | 2025 | Rexulti |
| Exact Sciences Corporation | $76.06 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $75.04 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $61.20 | 2023 | |
| Amarin Pharma, INC. | $53.37 | 2021-2022 | |
| Alkermes, INC. | $49.68 | 2023 | Vivitrol |
| Biohaven Pharmaceutical Holding Company LTD. | $39.22 | 2022 | |
| Sanofi-Aventis U.S. LLC | $35.89 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.64 | 2021-2025 | Jardiance |
| Corium, LLC | $35.55 | 2025 | Azstarys |
| Eisai INC. | $28.71 | 2021-2022 | |
| Tonix Medicines, INC. | $28.20 | 2025 | Tonmya |
| Kowa Pharmaceuticals America, INC. | $27.21 | 2022-2023 | Seglentis, Livalo |
| Idorsia Pharmaceuticals US INC | $22.48 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $21.57 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.57 | 2021 | |
| Biogen, INC. | $15.81 | 2021 | |
| Biodelivery Sciences International, INC. | $15.51 | 2021 | |
| Sumitomo Pharma America, INC. | $13.77 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ida Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.